Loading
Life sciences · Journal article
Journal of Clinical and Diagnostic Research · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The Retinol-binding Protein 4 (RBP4) has evolved as an important metabolic signal associated with insulin resistance and diabetes mellitus. Research shows that RBP4 increases early in metabolic stress and thus a potential marker for identifying individuals at risk for type 2 diabetes, gestational diabetes, and diabetic nephropathy. The present review highlights the RBP4’s biological function, its relationship with different states of glucose intolerance, and its potential clinical utility. RBP4 regulates various metabolic pathways which include impairing Glucose Transporter 4 (GLUT4) translocation, enhancing hepatic glucose production and inducing inflammatory pathways. These molecular effect explain the elevated serum RBP4 level in insulin-resistant states and rises even before the changes in fasting glucose or HbA1c. In type 2 diabetes, elevated RBP4 level associates with insulin resistance, dyslipidaemia, and central obesity. During pregnancy, women with elevated RBP4 in the first trimester develop gestational diabetes later, indicating that metabolic changes begin even before routine screening may detect. In diabetic nephropathy, RBP4 reflects early tubular injury and may rise prior to the onset of microalbuminuria. Currently, RBP4 has been considered as a sensitive marker of early metabolic disturbance and renal stress. Prospective studies with larger cohorts and standardised assay can establish RBP4 as part of multimarker panels for predicting diabetes mellitus and monitoring high-risk pregnancy and early kidney and vascular damage. The present review brings into perspective the biological relevance of RBP4, summarises its clinical correlates, and addresses the key challenges that need to be resolved before this protein finds routine applications in diabetes mellitus management.